Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 625 - 632 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC3668 | GNF-5837 |
|
Potent pan-Trk inhibitor. Displays antiproliferative effects in cellular Ba/F3 assays (IC<sub>50</sub> values are 7, 9 and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively). Exhibits selectivity for Trk receptors over a range of kinases, with some activity at PDGFR and c-Kit (IC<sub>50</sub> values are 0.87 and 0.91 <span class='symbol'>μ</span>M respectively). Orally bioavailable.
|
|
| BCC3669 | FR 180204 |
|
Selective ERK inhibitor (IC<sub>50</sub> values are 0.14 and 0.31 <span class='symbol'>μ</span>M for ERK2 and ERK1 respectively). Displays 30-fold selectivity for ERK over p38<span class='symbol'>α</span> (IC<sub>50</sub> = 10 <span class='symbol'>μ</span>M); displays no activity against human recombinant MEK1, MKK4, IKK<span class='symbol'>α</span>, PKC<span class='symbol'>α</span>, Src, Syc and PDGF<span class='symbol'>α</span> at concentrations less than 30 <span class='symbol'>μ</span>M. Also inhibits TGF<span class='symbol'>β</span>-induced AP-1 activation in Mv1Lu cells (IC<sub>50</sub> = 3.1 <span class='symbol'>μ</span>M).
|
|
| BCC3670 | MOG (35-55) |
|
Myelin oligodendrocyte glycoprotein (MOG) 35-55 is a minor component of CNS myelin. Produces a relapsing-remitting neurological disease with extensive plaque-like demyelination, common to the manifestations of multiple sclerosis. Induces strong T and B cell responses and is highly encephalitogenic.
|
|
| BCC3675 | Maraviroc |
|
Selective CCR5 antagonist; displays potent anti-HIV-1 activity. Prevents the interaction of HIV-1 gp120 and CCR5 (IC<sub>50</sub> = 6.4 nM), inhibiting HIV-1 entry. Exhibits antinociceptive effects in a rat model of neuropathic pain. Also inhibits CCL3 (MIP-1<span class='symbol'>α</span>) binding to CCR5. Orally bioavailable.
|
|
| BCC3676 | Torin 1 |
|
Potent and selective mTOR inhibitor (IC50 = 2 - 10 nM for mTORC1 and mTORC2). Displays 200-fold selectivity for mTOR over DNA-PK, ATM and hVps34. Induces autophagy in HeLa cells.
|
|
| BCC3678 | Temsirolimus |
|
mTOR inhibitor; inhibits tumor growth in breast cancer cell lines (IC<sub>50</sub> values are 1.6 and 4.3 nM for SKBr3 and BT474, respectively). Inhibits HIF-1<span class='symbol'>α</span>-mediated VEGF production in breast cancer cell lines (BT474 and MDA-MB-231). Directly inhibits serum and VEGF mediated endothelial cell proliferation and morphogenesis <em>in vitro</em> and vessel formation <em>in vivo</em>. Causes G<sub>1</sub>/S cell cycle arrest in multiple cancer cell lines. Antiangiogenic.
|
|
| BCC3679 | NU7441 (KU-57788) |
|
Potent and selective DNA-PK inhibitor (IC<sub>50</sub> = 14 nM). Selective for DNA-PK over a range of kinases including mTOR, PI 3-K, ATM and ATR. Potentiates the effects of doxorubicin and etoposide <em>in vitro</em> and etoposide <em>in vivo</em>. Also enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency 2 to 3-fold, and decreases nonhomologous end-joining (NHEJ) frequency ~40%.
|
|
| BCC3682 | PP242 |
|
ATP-competitive mTORC1/mTORC2 inhibitor (IC<sub>50</sub> = 8 nM). Displays selectivity for mTOR over other PI 3K family kinases (IC<sub>50</sub> values are 0.102, 0.408, 1.27, 1.96 and 2.2 <span class='symbol'>μ</span>M for p110<span class='symbol'>γ</span>, DNA-PK, p110<span class='symbol'>δ</span>, p110<span class='symbol'>α</span> and p110<span class='symbol'>β</span> respectively) and 215 further kinases. Displays modest inhibition of PKC<span class='symbol'>α</span>, JAK2, PKC<span class='symbol'>β</span>I, PKC<span class='symbol'>β</span>II and RET (IC<sub>50</sub> values are 0.049, 0.110, 0.185, 0.198 and 0.224 <span class='symbol'>μ</span>M respectively). Inhibits both S6K and 4EBP1 phosphorylation; activity causes a decrease in cap-dependent protein translation. Also triggers downregulation of cFLIP<sub>S</sub> and augments TRAIL-induced apoptosis of cancer cells.
|
|